Skip to main content
Mijn bibliotheek
Shop
Nieuws Boeken Tijdschriften E-learning Web-tv Video Audio
Tips voor Mijn BSL
UITGEBREID ZOEKEN
Inloggen
Top
Quality of Life Research
Gepubliceerd in: Quality of Life Research 11/2019

21-06-2019

Cortisol, oxytocin, and quality of life in major depressive disorder

Auteurs: Ai Ling Tang, Susan J. Thomas, Theresa Larkin

Gepubliceerd in: Quality of Life Research | Uitgave 11/2019

Log in om toegang te krijgen
share
DELEN

Deel dit onderdeel of sectie (kopieer de link)

  • Optie A:
    Klik op de rechtermuisknop op de link en selecteer de optie “linkadres kopiëren”
  • Optie B:
    Deel de link per e-mail
    Link delen
publish
Publiceer nu

Abstract

Purpose

Quality of life (QoL) is greatly impaired in major depressive disorder (MDD). These impairments are not fully accounted for by symptom severity, may persist beyond depressive episodes, and are a risk factor for poor outcomes. MDD is often associated with prominent neuroendocrine changes and increased risk of chronic disease. However, there is a lack of research examining whether biological factors are related to QoL in MDD. This research examined relationships between cortisol, oxytocin, symptom severity, and QoL in MDD.

Methods

Sixty adults meeting DSM-5 criteria for MDD and 60 healthy controls provided morning plasma samples which were analysed for cortisol and oxytocin levels, and completed measures of QoL and psychopathology.

Results

Participants with MDD had lower QoL than controls. Cortisol correlated negatively with overall QoL and all QoL domains. Oxytocin correlated positively with overall QoL, and Psychological and Social-Relationships domains. Additionally, cortisol levels were inversely related to psychological QoL, and oxytocin was positively related to social QoL, after controlling for symptom severity and demographic variables.

Conclusions

This study provides novel evidence linking neuroendocrine pathways to particular domains of QoL in MDD. The results indicate that activity of the hypothalamic–pituitary–adrenal axis is linked to poor psychological QoL, and that oxytocin is important to social QoL, independently of severity of psychopathology. Biopsychosocial approaches to QoL associated with mental health conditions may lead to greater understanding of the underlying mechanisms and to improved, tailored interventions.
vorige artikel The importance of face-to-face contact and reciprocal relationships and their associations with depressive symptoms and life satisfaction
volgende artikel Exploring the patient experience of locally advanced or metastatic pancreatic cancer to inform patient-reported outcomes assessment
Literatuur
1.
Ritsner, M. S. (2007). The distress/protection vulnerability model of quality of life impairment syndrome. In M. S. Ritsner & A. G. Awad (Eds.), Quality of life impairment in schizophrenia, mood and anxiety disorders: New perspectives on research and treatment (pp. 3–19). Springer: Dordrecht.CrossRef
2.
The World Health Organization Group. (1998). The World Health Organization quality of life assessment (WHOQOL): Development and general psychometric properties. Social Science and Medicine, 46(12), 1569–1585.CrossRef
3.
Bonicatto, S. C., et al. (2001). Adult outpatients with depression: Worse quality of life than in other chronic medical diseases in Argentina. Social Science and Medicine, 52(6), 911–919.PubMedCrossRef
4.
IsHak, W. W., et al. (2011). Quality of life: The ultimate outcome measure of interventions in major depressive disorder. Harvard Review of Psychiatry, 19(5), 229–239.PubMedCrossRef
5.
da Rocha, N. S., et al. (2009). Is there a measurement overlap between depressive symptoms and quality of life? Comprehensive Psychiatry, 50(6), 549–555.PubMedCrossRef
6.
Papakostas, G. I., et al. (2004). Quality of life assessments in major depressive disorder: A review of the literature. General Hospital Psychiatry, 26(1), 13–17.PubMedCrossRef
7.
Meltzer-Brody, S., & Davidson, J. R. (2000). Completeness of response and quality of life in mood and anxiety disorders. Depression and Anxiety, 12(S1), 95–101.PubMedCrossRef
8.
Keating, C., et al. (2013). Effects of selective serotonin reuptake inhibitor treatment on plasma oxytocin and cortisol in major depressive disorder. BMC Psychiatry, 13, 124.PubMedPubMedCentralCrossRef
9.
Penninx, B. W. J. H. (2017). Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. Neuroscience and Biobehavioral Reviews, 74, 277–286.PubMedCrossRef
10.
Neumann, I. D. (2008). Brain oxytocin: A key regulator of emotional and social behaviours in both females and males. Journal of Neuroendocrinology, 20(6), 858–865.PubMedCrossRef
11.
Cochran, D., et al. (2013). The role of oxytocin in psychiatric disorders: A review of biological and therapeutic research findings. Harvard Review of Psychiatry, 21(5), 219–247.PubMedPubMedCentralCrossRef
12.
Parker, K. J., et al. (2010). Preliminary evidence that plasma oxytocin levels are elevated in major depression. Psychiatry Research, 178(2), 359–362.PubMedPubMedCentralCrossRef
13.
Slattery, D. A., & Neumann, I. D. (2010). Oxytocin and major depressive disorder: Experimental and clinical evidence for links to aetiology and possible treatment. Pharmaceuticals, 3(3), 702–724.PubMedPubMedCentralCrossRef
14.
Holsboer, F., & Ising, M. (2010). Stress hormone regulation: Biological role and translation into therapy. Annual Review of Psychology, 61(1), 81–109.PubMedCrossRef
15.
Pariante, C. M., & Lightman, S. L. (2008). The HPA axis in major depression: Classical theories and new developments. Trends in Neurosciences, 31(9), 464–468.PubMedCrossRef
16.
Burke, H. M., et al. (2005). Depression and cortisol responses to psychological stress: A meta-analysis. Psychoneuroendocrinology, 30(9), 846–856.PubMedCrossRef
17.
Zunszain, P. A., et al. (2011). Glucocorticoids, cytokines and brain abnormalities in depression. Progress in Neuro-Psychopharmacology and Biological Psychiatry, 35(3), 722–729.PubMedCrossRef
18.
Raison, C. L., & Miller, A. H. (2003). When not enough is too much: The role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. American Journal of Psychiatry, 160(9), 1554–1565.CrossRef
19.
Kessler, R. C., et al. (2010). Childhood adversities and adult psychopathology in the WHO World Mental Health Surveys. The British Journal of Psychiatry, 197(5), 378–385.PubMedPubMedCentralCrossRef
20.
Booij, S. H., et al. (2016). The temporal dynamics of cortisol and affective states in depressed and non-depressed individuals. Psychoneuroendocrinology, 69, 16–25.PubMedCrossRef
21.
Steptoe, A., et al. (2007). Neuroendocrine and inflammatory factors associated with positive affect in healthy men and women: The Whitehall II study. American Journal of Epidemiology, 167(1), 96–102.PubMedCrossRef
22.
Hardeveld, F., et al. (2014). Increased cortisol awakening response was associated with time to recurrence of major depressive disorder. Psychoneuroendocrinology, 50, 62–71.PubMedCrossRef
23.
Peeters, F., Nicolson, N. A., & Berkhof, J. (2004). Levels and variability of daily life cortisol secretion in major depression. Psychiatry Research, 126(1), 1–13.PubMedCrossRef
24.
Knuth, B. S., et al. (2016). Stress, depression, quality of life and salivary cortisol levels in community health agents. Acta Neuropsychiatrica, 28(3), 165–172.PubMedCrossRef
25.
Carlson, L. E., et al. (2004). Mindfulness-based stress reduction in relation to quality of life, mood, symptoms of stress and levels of cortisol, dehydroepiandrosterone sulfate (DHEAS) and melatonin in breast and prostate cancer outpatients. Psychoneuroendocrinology, 29(4), 448–474.PubMedCrossRef
26.
Mutsuura, H., et al. (2009). Depression and anxiety correlate differently with salivary free cortisol in the morning in patients with functional somatic syndrome. Applied Psychophysiology and Biofeedback, 34(4), 291–298.PubMedPubMedCentralCrossRef
27.
Windle, R. J., et al. (2006). Gonadal steroid modulation of stress-induced hypothalamo–pituitary–adrenal activity and anxiety behavior: Role of central oxytocin. Endocrinology, 147(5), 2423–2431.PubMedCrossRef
28.
Faul, F., et al. (2007). G* Power 3: A flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behavior Research Methods, 39(2), 175–191.PubMedCrossRef
29.
Thomas, S., & Larkin, T. (2018). Plasma cortisol and oxytocin levels predict help-seeking intentions for depressive symptoms. Psychoneuroendocrinology, 87, 159–165.PubMedCrossRef
30.
World Health Organization. (1997). WHOQOL: Measuring quality of life. Geneva: World Health Organization.
31.
Derogatis, L., & Melisaratos, N. (1983). The brief symptom inventory: An introductory report. Psychological Medicine, 13(3), 595–605.PubMedCrossRef
32.
Mohammadkhani, P., et al. (2010). Psychometric properties of the Brief Symptom Inventory in a sample of recovered Iranian depressed patients. International Journal of Clinical and Health Psychology, 10(3), 541–551.
33.
Lecrubier, Y., et al. (1997). The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: Reliability and validity according to the CIDI. European Psychiatry, 12(5), 224–231.CrossRef
34.
Pollet, T., & Meij, L. (2017). To remove or not to remove: The impact of outlier handling on significance testing in testosterone data. Adaptive Human Behavior & Physiology, 3(1), 43.CrossRef
35.
Wilcox, R. R., et al. (2014). Cortisol diurnal patterns, associations with depressive symptoms, and the impact of intervention in older adults: Results using modern robust methods aimed at dealing with low power due to violations of standard assumptions. Hormones and Behavior, 65(3), 219–225.PubMedPubMedCentralCrossRef
36.
Field, A. (2009). Discovering statistics using SPSS (3rd ed.). London: Sage.
37.
Tabachnick, B. G., & Fidell, L. S. (2007). Using multivariate statistics (5th ed.). Boston: Allyn & Bacon.
38.
Howell, D. C. (2013). Statistical methods for psychology (8th ed.). Canada: Wadsworth.
39.
Holubova, M., et al. (2016). Self-stigma and quality of life in patients with depressive disorder: A cross-sectional study. Neuropsychiatric Disease and Treatment, 12, 2677–2687.PubMedPubMedCentralCrossRef
40.
IsHak, W. W., et al. (2015). Quality of life in major depressive disorder before/after multiple steps of treatment and one-year follow-up. Acta Psychiatrica Scandinavica, 131(1), 51–60.PubMedCrossRef
41.
Trivedi, M. H., et al. (2006). Factors associated with health-related quality of life among outpatients with major depressive disorder: A STAR*D report. The Journal of Clinical Psychiatry, 67(2), 185–195.PubMedCrossRef
42.
Ryan, C. (2007). British outpatient norms for the Brief Symptom Inventory. Psychology and Psychotherapy: Theory, Research and Practice, 80(2), 183–191.CrossRef
43.
Myers, B., McKlveen, J. M., & Herman, J. P. (2014). Glucocorticoid actions on synapses, circuits, and behavior: Implications for the energetics of stress. Frontiers in Neuroendocrinology, 35(2), 180–196.PubMedCrossRef
44.
Pariante, C. M., & Miller, A. H. (2001). Glucocorticoid receptors in major depression: Relevance to pathophysiology and treatment. Biological Psychiatry, 49(5), 391–404.PubMedCrossRef
45.
Anderberg, U. M., & Uvnäs-Moberg, K. (2000). Plasma oxytocin levels in female fibromyalgia syndrome patients. Zeitschrift fur Rheumatologie, 59(6), 373–379.PubMedCrossRef
46.
Gordon, I., et al. (2008). Oxytocin and cortisol in romantically unattached young adults: Associations with bonding and psychological distress. Psychophysiology, 45(3), 349–352.PubMedCrossRef
47.
McQuaid, R. J., et al. (2014). Making room for oxytocin in understanding depression. Neuroscience and Biobehavioral Reviews, 45, 305–322.PubMedCrossRef
48.
Zhong, S., et al. (2012). U-shaped relation between plasma oxytocin levels and behavior in the trust game. PLoS ONE, 7(12), 1–9.CrossRef
49.
Sapolsky, R. M. (2000). Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Archives of General Psychiatry, 57(10), 925–935.PubMedCrossRef
50.
Lupien, S. J., et al. (2009). Effects of stress throughout the lifespan on the brain, behaviour and cognition. Nature Reviews Neuroscience, 10(6), 434–445.PubMedCrossRef
51.
Angermeyer, M., et al. (2002). Depression and quality of life: Results of a follow-up study. International Journal of Social Psychiatry, 48(3), 189–199.CrossRef
52.
Baudrand, R., & Vaidya, A. (2015). Cortisol dysregulation in obesity-related metabolic disorders. Current Opinion in Endocrinology, Diabetes, and Obesity, 22(3), 143–149.PubMedPubMedCentralCrossRef
53.
Chellew, K., et al. (2015). The effect of progressive muscle relaxation on daily cortisol secretion. Stress, 18, 538–544.PubMedCrossRef
54.
Matousek, R. H., Dobkin, P. L., & Pruessner, J. (2010). Cortisol as a marker for improvement in mindfulness-based stress reduction. Complementary Therapies in Clinical Practice, 16(1), 13–19.PubMedCrossRef
55.
Hanley, J. A. (2017). Correction of selection bias in survey data: Is the statistical cure worse than the bias? American Journal of Public Health, 107(4), 503–505.PubMedPubMedCentralCrossRef
Metagegevens
Titel
Cortisol, oxytocin, and quality of life in major depressive disorder
Auteurs
Ai Ling Tang
Susan J. Thomas
Theresa Larkin
Publicatiedatum
21-06-2019
Uitgeverij
Springer International Publishing
Gepubliceerd in
Quality of Life Research / Uitgave 11/2019
Print ISSN: 0962-9343
Elektronisch ISSN: 1573-2649
DOI
https://doi.org/10.1007/s11136-019-02236-3

Andere artikelen Uitgave 11/2019

Quality of Life Research 11/2019 Naar de uitgave

OriginalPaper

Patient-reported outcomes as predictors of survival in patients with bowel cancer: a systematic review

OriginalPaper

Disabled life expectancy with and without stroke: a 10-year Japanese prospective cohort study

OriginalPaper

Changes in taste among pediatric patients with cancer and hematopoietic stem cell transplantation recipients

OriginalPaper

Cancer survivor perspectives on sharing patient-generated health data with central cancer registries

OriginalPaper

Emotional problems and health-related quality of life: population-based study

OriginalPaper

Differential item functioning of the CAHPS® In-Center Hemodialysis Survey